HighLife announced today that it received CE mark approval for its transcatheter mitral valve replacement (TMVR) system.

Almost 20 years’ worth of follow-up in an international registry shows that patients with degenerative mitral regurgitation who underwent mitral valve (MV) repair had better survival, fewer ...

HighLife Receives CE Mark Approval for its TMVR SolutionParis, January 26, 2026 – HighLife SAS, a leading MedTech company focused on ...

With nine new procedures cleared for the da Vinci 5 robot, Intuitive’s strategy includes working with a limited number of U.S ...

Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...

Bioprosthetic valves lasts about 10-15 years. These are usually obtained from animals or human organ donors. Tissue valves seem to improve the patient’s hemodynamics, but tend to stiffen in 10-15 ...

Please provide your email address to receive an email when new articles are posted on . Among patients who underwent transcatheter mitral valve replacement for severe mitral regurgitation, 93% of ...

Patient will be placed under general anesthesia. An endotracheal tube will be inserted into the patient’s windpipe and connected to a ventilator to assist the patient’s breathing. Another probe will ...

Please provide your email address to receive an email when new articles are posted on . At 30 days, a group of 15 patients who underwent transfemoral transcatheter mitral valve replacement for ...

Edwards Lifesciences is paying up to $690 million to a buy an Israeli company that makes transcatheter mitral valve and tricuspid repair devices. Last year it bought a mitral valve replacement company ...

Research, along with guidelines from the American Heart Association® (AHA), indicates that patients who have primary mitral regurgitation would benefit from mitral valve repair rather than replacement ...

CONGENITAL mitral stenosis, sufficiently severe to cause recurrent heart failure and syncopal episodes in infancy, is rarely compatible with life beyond two years of age. 1 Except for 1 reported case ...